Improvements with tiotropium in COPD patients with concomitant asthma.

[1]  D. Dusser,et al.  The effect of tiotropium on exacerbations and airflow in patients with COPD , 2006, European Respiratory Journal.

[2]  V. Brusasco,et al.  Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. , 2003, Thorax.

[3]  D. Niewoehner,et al.  Prevention of Exacerbations of Chronic Obstructive Pulmonary Disease with Tiotropium, a Once-Daily Inhaled Anticholinergic Bronchodilator , 2005, Annals of Internal Medicine.

[4]  E. Israel,et al.  Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial , 2004, The Lancet.

[5]  B. Make,et al.  Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD , 2004, European Respiratory Journal.

[6]  W. MacNee,et al.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.

[7]  Joan B Soriano,et al.  The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. , 2003, Chest.

[8]  D. Tashkin,et al.  Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. , 2003, Chest.

[9]  L. Corbetta,et al.  Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. , 2003, American journal of respiratory and critical care medicine.

[10]  R. Zuwallack,et al.  A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease , 2002, European Respiratory Journal.

[11]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[12]  T L Petty,et al.  Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. , 2000, Archives of internal medicine.

[13]  C. Rodrigo,et al.  A meta-analysis of the effects of ipratropium bromide in adults with acute asthma. , 1999, The American journal of medicine.

[14]  S. Wenzel,et al.  Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. , 1999, American journal of respiratory and critical care medicine.

[15]  K. Richter,et al.  Are chronic obstructive pulmonary disease (COPD) and asthma different diseases? , 1998, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[16]  J. FitzGerald,et al.  The effect of adding ipratropium bromide to salbutamol in the treatment of acute asthma: a pooled analysis of three trials. , 1998, Chest.

[17]  P. Jeffery,et al.  Structural and inflammatory changes in COPD: a comparison with asthma. , 1998, Thorax.

[18]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[19]  John L. Hankinson,et al.  Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[20]  L. Fabbri,et al.  Airway eosinophilia in chronic bronchitis during exacerbations. , 1994, American journal of respiratory and critical care medicine.

[21]  A. Rebuck,et al.  Is the short-term response to inhaled beta-adrenergic agonist sensitive or specific for distinguishing between asthma and COPD? , 1994, Chest.

[22]  N. Pride,et al.  A "splitting" look at chronic nonspecific lung disease (CNSLD): common features but diverse pathogenesis. , 1991, The European respiratory journal.